20 June 2018

South Africa: A New Revolution in TB Treatment as the Injection Falls

Photo: Sydelle WIllow Smith/MSF
A South African XDR-TB patient receiving his Bedaquiline and delamanid.
press release

South Africa has just made history today as it becomes the first country in the world to take a bold step of replacing an injectable drug with toxic side effects, with a promising new oral medicine (bedaquiline) in the standard multidrug-resistant tuberculosis (MDR-TB) treatment regimens for adolescents and adults.

Doctors Without Borders (MSF) has welcomed the South African National Department of Health (NDoH)’s announcement and sees this as a positive step aimed at making MDR-TB treatment more tolerable, and reducing the devastating impact of side effects caused by the injectable agents.

“The standard treatment for MDR-TB is currently effective only 50% of the time, and includes a painful injectable antibiotic known to cause terrible toxic side effects, including kidney failure and hearing loss. Experience with bedaquiline in treating drug-resistant TB – mainly from South Africa - demonstrates improved clinical outcomes in people living with MDR-TB, and initial evidence shows that it can be safely and effectively used in place of the toxic injectable,” says MSF’s Dr. Anja Reuter, a DR-TB doctor in Khayelitsha in the Western Cape, where MSF has run a DR-TB programme since 2007.

Although there are still some hurdles in implementation, MSF has called on the government to support health facilities in developing capacity to use bedaquiline and other new drugs, and to manufacturers to reduce the prices they charge in South Africa and globally. Worldwide, more than half a million people are infected with MDR-TB every year but extremely few who could have benefited had access to newer TB drugs such as bedaquiline.

MSF is urging other countries and officials responsible for WHO guidance on the use of DR-TB medicines to follow South Africa’s progressive example and commit to replacing the toxic injectable drug and ensuring expanded global access to effective new medicines, including bedaquiline.

More on This

Health Dept Releases Data On Reduction in TB Mortality Cases

The Department of Health has released new data on reduction in TB mortality cases from drug resistant Tuberculosis (DR -… Read more »

See What Everyone is Watching

Copyright © 2018 Medecins Sans Frontieres. All rights reserved. Distributed by AllAfrica Global Media (allAfrica.com). To contact the copyright holder directly for corrections — or for permission to republish or make other authorized use of this material, click here.

AllAfrica publishes around 800 reports a day from more than 140 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.